Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06634979

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

Led by Fudan University · Updated on 2025-08-12

684

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.

CONDITIONS

Official Title

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
  • Age 18-80 years at time of signing informed consent (including threshold);
  • ECOG score 0 or 1;
  • No previous surgery for lung cancer;
  • Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
  • Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
  • The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
  • Patients with clinical stage T1N0M0 surgically resectable;
  • Primary treatment without radiotherapy or chemotherapy.
Not Eligible

You will not qualify if you...

  • T1N0M0 with a clinical stage other than 0.5 < CTR < 1 and a diameter of ≤ 2 cm;
  • Inability to perform complete surgical resection;
  • cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
  • Previous surgery for lung cancer;
  • Patients who have received radiotherapy or chemotherapy for non-primary treatment.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, China

Actively Recruiting

Loading map...

Research Team

P

Penghao Deng

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here